5F-AB-FUPPYCA

5F-AB-FUPPYCA
Legal status
Legal status	CA: Schedule II ;
Identifiers
	IUPAC name N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide;
CAS Number	None;
ChemSpider	58191440;
Chemical and physical data
Formula	C20H26F2N4O2
Molar mass	392.451 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC(C(C(C)C)NC(=O)C1=NN(C(=C1)C1=CC=C(C=C1)F)CCCCCF)=O;
	InChI InChI=1/C20H26F2N4O2/c1-13(2)18(19(23)27)24-20(28)16-12-17(14-6-8-15(22)9-7-14)26(25-16)11-5-3-4-10-21/h6-9,12-13,18H,3-5,10-11H2,1-2H3,(H2,23,27)(H,24,28)/f/h24H,23H2; Key:GSXRDTDYPSATDE-UHFFFAOYSA-N;

5F-AB-FUPPYCA (also known as AZ-037) is a pyrazole-based synthetic cannabinoid that is presumed to be an agonist of the CB₁ receptor and has been sold online as a designer drug.[1][2] It was first detected by the EMCDDA as part of a seizure of 540 g white powder in France in February 2015.[3]

The name AZ-037 is also used as a synonym for its structural isomer 5-fluoro-3,5-AB-PFUPPYCA.[4] Thus AZ-037 is being used as a synonym for two different compounds.

References

Girreser, Ulrich; Rösner, Peter; Vasilev, Andrej (July 2016). "Structure elucidation of the designer drug N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-3-(4-fluorophenyl)-pyrazole-5-carboxamide and the relevance of predicted 13C NMR shifts – a case study". Drug Testing and Analysis. 8 (7): 668–675. doi:10.1002/dta.1820. ISSN 1942-7611. PMID 26012418.
Banister, Samuel D.; Longworth, Mitchell; Kevin, Richard; Sachdev, Shivani; Santiago, Marina; Stuart, Jordyn; Mack, James B. C.; Glass, Michelle; McGregor, Iain S.; Connor, Mark; Kassiou, Michael (27 July 2016). "Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues". ACS Chemical Neuroscience. 7 (9): 1241–54. doi:10.1021/acschemneuro.6b00137. PMID 27421060.
"2015. ÉVI EURÓPAI KÁBÍTÓSZER - JELENTÉS - A MONITOROZÁS 20 ÉVE" (PDF). Hungarian National Focal Point (NFP). June 2015. Retrieved 23 July 2015.
"5-fluoro-3,5-AB-PFUPPYCA". Cayman Chemical Company. Retrieved 11 February 2016.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Girreser, Ulrich; Rösner, Peter; Vasilev, Andrej (July 2016). "Structure elucidation of the designer drug N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-3-(4-fluorophenyl)-pyrazole-5-carboxamide and the relevance of predicted 13C NMR shifts – a case study". Drug Testing and Analysis. 8 (7): 668–675. doi:10.1002/dta.1820. ISSN 1942-7611. PMID 26012418.

[2] Banister, Samuel D.; Longworth, Mitchell; Kevin, Richard; Sachdev, Shivani; Santiago, Marina; Stuart, Jordyn; Mack, James B. C.; Glass, Michelle; McGregor, Iain S.; Connor, Mark; Kassiou, Michael (27 July 2016). "Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues". ACS Chemical Neuroscience. 7 (9): 1241–54. doi:10.1021/acschemneuro.6b00137. PMID 27421060.

[3] "2015. ÉVI EURÓPAI KÁBÍTÓSZER - JELENTÉS - A MONITOROZÁS 20 ÉVE" (PDF). Hungarian National Focal Point (NFP). June 2015. Retrieved 23 July 2015.

[4] "5-fluoro-3,5-AB-PFUPPYCA". Cayman Chemical Company. Retrieved 11 February 2016.

5F-AB-FUPPYCA

See also

References